Boiron SA BOIRF Stock
Boiron SA Price Chart
Boiron SA BOIRF Financial and Trading Overview
| Boiron SA stock price | 30 USD |
| Previous Close | 30 USD |
| Open | 30 USD |
| Bid | 28.45 USD x 10000 |
| Ask | 31.55 USD x 10000 |
| Day's Range | 30 - 30 USD |
| 52 Week Range | 24 - 32.28 USD |
| Volume | 200 USD |
| Avg. Volume | 4 USD |
| Market Cap | 520.87M USD |
| Beta (5Y Monthly) | 0.225 |
| PE Ratio (TTM) | 13.888888 |
| EPS (TTM) | 2.16 USD |
| Forward Dividend & Yield | 1.57 (4.90%) |
| Ex-Dividend Date | June 3, 2026 |
| 1y Target Est | N/A |
BOIRF Valuation Measures
| Enterprise Value | 506.02M USD |
| Trailing P/E | 13.888888 |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 1.0394374 |
| Price/Book (mrq) | 1.1464396 |
| Enterprise Value/Revenue | 1.01 |
| Enterprise Value/EBITDA | 7.318 |
Trading Information
Boiron SA Stock Price History
| Beta (5Y Monthly) | 0.225 |
| 52-Week Change | 11.92% |
| S&P500 52-Week Change | 22.66% |
| 52 Week High | 32.28 USD |
| 52 Week Low | 24 USD |
| 50-Day Moving Average | 30.87 USD |
| 200-Day Moving Average | 29.22 USD |
BOIRF Share Statistics
| Avg. Volume (3 month) | 4 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 17.36M |
| Float | 3.5M |
| Short Ratio | N/A |
| % Held by Insiders | 79.00% |
| % Held by Institutions | 5.33% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 1.35 |
| Trailing Annual Dividend Yield | 4.50% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0.6383 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | December 31, 2025 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 6.51% |
| Operating Margin (ttm) | 11.59% |
| Gross Margin | 72.98% |
| EBITDA Margin | 13.80% |
Management Effectiveness
| Return on Assets (ttm) | 5.46% |
| Return on Equity (ttm) | 8.46% |
Income Statement
| Revenue (ttm) | 501.11M USD |
| Revenue Per Share (ttm) | 28.86 USD |
| Quarterly Revenue Growth (yoy) | -1.40% |
| Gross Profit (ttm) | 365.72M USD |
| EBITDA | 69.15M USD |
| Net Income Avi to Common (ttm) | 32.64M USD |
| Diluted EPS (ttm) | 2.16 |
| Quarterly Earnings Growth (yoy) | 165.90% |
Balance Sheet
| Total Cash (mrq) | 79.34M USD |
| Total Cash Per Share (mrq) | 4.57 USD |
| Total Debt (mrq) | 31.48M USD |
| Total Debt/Equity (mrq) | 8.02 USD |
| Current Ratio (mrq) | 2.222 |
| Book Value Per Share (mrq) | 26.167973 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 53.24M USD |
| Levered Free Cash Flow (ttm) | 53.06M USD |
Profile of Boiron SA
| Country | United States |
| State | N/A |
| City | Messimy |
| Address | 2, avenue de l’Ouest Lyonnais |
| ZIP | 69510 |
| Phone | 33 4 78 45 61 00 |
| Website | https://www.boiron.fr |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector(s) | Healthcare |
| Full Time Employees | 2364 |
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is based in Messimy, France.
Q&A For Boiron SA Stock
What is a current BOIRF stock price?
Boiron SA BOIRF stock price today per share is 30 USD.
How to purchase Boiron SA stock?
You can buy BOIRF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Boiron SA?
The stock symbol or ticker of Boiron SA is BOIRF.
Which industry does the Boiron SA company belong to?
The Boiron SA industry is Drug Manufacturers - Specialty & Generic.
How many shares does Boiron SA have in circulation?
The max supply of Boiron SA shares is 17.36M.
What is Boiron SA Price to Earnings Ratio (PE Ratio)?
Boiron SA PE Ratio is 13.88888800 now.
What was Boiron SA earnings per share over the trailing 12 months (TTM)?
Boiron SA EPS is 2.16 USD over the trailing 12 months.
Which sector does the Boiron SA company belong to?
The Boiron SA sector is Healthcare.